Henlius Reports First Fully Profitable Year After Past Losses

The Result Continues The Trend Of Increased Sales Growth

After reporting losses for the past two years, the Chinese pharma announced the first full year of profitability on the back of continued sales of its commercialized assets.

China flag, vial dose, needle syringe
• Source: Shutterstock

Shanghai Henlius Biotech has achieved its first full year of profitability in 2023 on the back of increased sales and growing sales volume, marking a change from the last two years’ of reported losses.

The Chinese company reported a net profit of RMB546m ($75.72m) in the reporting period that ended with the turn of...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business